These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38553802)

  • 1. The diagnostic and prognostic value of tau-PET in amnestic MCI with different FDG-PET subtypes.
    Boccalini C; Caminiti SP; Chiti A; Frisoni GB; Garibotto V; Perani D;
    Ann Clin Transl Neurol; 2024 May; 11(5):1236-1249. PubMed ID: 38553802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.
    Coutinho AM; Porto FH; Duran FL; Prando S; Ono CR; Feitosa EA; Spíndola L; de Oliveira MO; do Vale PH; Gomes HR; Nitrini R; Brucki SM; Buchpiguel CA
    Alzheimers Res Ther; 2015 Sep; 7(1):58. PubMed ID: 26373380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A biomarker study in long-lasting amnestic mild cognitive impairment.
    Cerami C; Dodich A; Iannaccone S; Magnani G; Santangelo R; Presotto L; Marcone A; Gianolli L; Cappa SF; Perani D
    Alzheimers Res Ther; 2018 Apr; 10(1):42. PubMed ID: 29695292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
    Eliassen CF; Reinvang I; Selnes P; Grambaite R; Fladby T; Hessen E
    Brain Behav; 2017 Sep; 7(9):e00776. PubMed ID: 28948074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker-based stability in limbic-predominant amnestic mild cognitive impairment.
    Tondo G; Carli G; Santangelo R; Mattoli MV; Presotto L; Filippi M; Magnani G; Iannaccone S; Cerami C; Perani D;
    Eur J Neurol; 2021 Apr; 28(4):1123-1133. PubMed ID: 33185922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters.
    Coutinho AM; Busatto GF; de Gobbi Porto FH; de Paula Faria D; Ono CR; Garcez AT; Squarzoni P; de Souza Duran FL; de Oliveira MO; Tres ES; Brucki SMD; Forlenza OV; Nitrini R; Buchpiguel CA
    Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2666-2680. PubMed ID: 32055966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis.
    Botha H; Mantyh WG; Murray ME; Knopman DS; Przybelski SA; Wiste HJ; Graff-Radford J; Josephs KA; Schwarz CG; Kremers WK; Boeve BF; Petersen RC; Machulda MM; Parisi JE; Dickson DW; Lowe V; Jack CR; Jones DT
    Brain; 2018 Apr; 141(4):1201-1217. PubMed ID: 29538658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
    Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
    Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG-PET markers of heterogeneity and different risk of progression in amnestic MCI.
    Caminiti SP; De Francesco S; Tondo G; Galli A; Redolfi A; Perani D; ;
    Alzheimers Dement; 2024 Jan; 20(1):159-172. PubMed ID: 37505996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnestic MCI.
    Tripathi M; Tripathi M; Parida GK; Kumar R; Dwivedi S; Nehra A; Bal C
    Neurol India; 2019; 67(5):1310-1317. PubMed ID: 31744965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau positron emission tomography using [
    Kang JM; Lee SY; Seo S; Jeong HJ; Woo SH; Lee H; Lee YB; Yeon BK; Shin DH; Park KH; Kang H; Okamura N; Furumoto S; Yanai K; Villemagne VL; Seong JK; Na DL; Ido T; Cho J; Lee KM; Noh Y
    Neurobiol Aging; 2017 Nov; 59():210-219. PubMed ID: 28890300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
    Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
    Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology.
    Silva-Rodríguez J; Labrador-Espinosa MA; Moscoso A; Schöll M; Mir P; Grothe MJ;
    Brain; 2023 Nov; 146(11):4520-4531. PubMed ID: 37284793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum.
    Nihashi T; Sakurai K; Kato T; Iwata K; Kimura Y; Ikenuma H; Yamaoka A; Takeda A; Arahata Y; Washimi Y; Suzuki K; Bundo M; Sakurai T; Okamura N; Yanai K; Ito K; Nakamura A;
    J Alzheimers Dis; 2022; 85(1):223-234. PubMed ID: 34776443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
    Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
    JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
    Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
    Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.